Changes critical to persistent lowering of arterial pressure in spontaneously hypertensive rat occur early in antihypertensive treatment

Journal of Hypertension

Volumn 29, Issue 1, 2011, Pages 113-122

  Hale, Taben M ^a   Bushfield, Terri L ^a   Woolard, Jeanette ^a   Pang, Judy J ^a   Rees Milton, Karen J ^a   Adams, Michael A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

antihypertensive agents; arterial pressure; endothelin; experimental; hypertension; inbred spontaneously hypertensive rat; rats; vascular resistance

Indexed keywords

ENALAPRIL; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; HYPERTENSION; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MESENTERIC VEIN; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TISSUE LEVEL; VASCULAR RESISTANCE;

EID: 78650837443     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833fb7cb     Document Type: Article

References (48)

1. Hale TM, Shoichet MJ, Bushfield TL, Adams MA. Time course of vascular structural changes during and after short-term antihypertensive treatment. Hypertension 2003; 42:171-176.
2. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Cinelli A, et al. Prolonged effects of short-term fosinopril on blood pressure and vascular morphology and function inrats. Am J Hypertens1997; 10 (9 Pt 1):1034-1043.
3. Naelten G, Liu KL, Chapuis B, Lo M. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats. Am J Hypertens 2005; 18:699-706.
4. Smallegange C, Hale TM, Bushfield TL, Adams MA. Persistent lowering of pressure by transplanting kidneys from adult spontaneously hypertensive rats treated with brief antihypertensive therapy. Hypertension 2004; 44:89-94.
5. Smallegange C, Kline RL, Adams MA. Transplantation of enalapril-treated kidneys confers persistent lowering of arterial pressure in SHR. Hypertension 2003; 42:932-936.
6. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti R. Delayed development of hypertension after short-term nitrendipine treatment. Hypertension 1994; 24:131-139.
7. Lundie MJ, Friberg P, Kline RL, Adams MA. Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. J Hypertens 1997; 15:339-348.
8. Sharifi AM, Li JS, Endemann D, Schiffrin EL. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 1998; 16:457-466.
9. De Blois D, Tea BS, Than VD, Tremblay J, Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 1997; 29 (1 Pt 2):340-349.
10. Paull JR, Widdop RE. Persistent cardiovascular effects of chronic renin- angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. J Hypertens 2001; 19:1393-1402.
11. Ledingham JM, Laverty R. Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Clin Exp Pharmacol Physiol 1996; 23:576-578.
12. Jespersen LT, Nyborg NC, Pedersen OL, Mikkelsen EO, Mulvany MJ. Cardiac mass and peripheral vascular structure in hydralazine-treated spontaneously hypertensive rats. Hypertension 1985; 7:734-741.
13. Sharifi AM, Schiffrin EL. Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Am J Hypertens 1998; 11:1108-1116.
14. Marchand EL, Der SS, Hamet P, deBlois D. Caspase-dependent cell death mediates the early phase of aortic hypertrophy regression in losartan-treated spontaneously hypertensive rats. Circ Res 2003; 92:777-784.
15. Webb RL, Navarrete AE, Davis S. Effects of valsartan and hydrochlorothiazide alone and in combination on blood pressure and heart rate in conscious-telemetered spontaneously hypertensive rats (SHR). Am J Hypertens 1998; 11 (1 Pt 1):59-65.
16. Richard V, Hogie M, Thuillez C. Angiotensin II receptor blockade unmasks a depressor response to endothelin antagonists in rats. Fundam Clin Pharmacol 2000; 14:101-106.
17. Bohlender J, Gerbaulet S, Kramer J, Gross M, Kirchengast M, Dietz R. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 2000; 35:992-997.
18. Donckier JE, Massart PE, Hodeige D, Van Mechelen H, Clozel JP, Laloux O, et al. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation 1997; 96:1250-1256.
19. Hale TM, Okabe H, Bushfield TL, Heaton JP, Adams MA. Recovery of erectile function after brief aggressive antihypertensive therapy. J Urol 2002; 168:348-354.
20. Hale TM, Okabe H, Heaton JP, Adams MA. Antihypertensive drugs induce structural remodeling of the penile vasculature. J Urol 2001; 166:739-745.
21. Banting JD, Thompson KE, Friberg P, Adams MA. Blunted cardiovascular growth induction during prolonged nitric oxide synthase blockade. Hypertension 1997; 30 (3 Pt 1):416-421.
22. Mulvany MJ, Hansen OK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res 1978; 43:854-864.
23. Ratz JD, Fraser AB, Rees-Milton KJ, Adams MA, Bennett BM. Endothelin receptor antagonism does not prevent the development of in vivo glyceryl trinitrate tolerance in the rat. J Pharmacol Exp Ther 2000; 295:578-585.
24. Shaver SW, Pang JJ, Wainman DS, Wall KM, Gross PM. Morphology and function of capillary networks in subregions of the rat tuber cinereum. Cell Tissue Res 1992; 267:437-448.
25. Reynolds EE, Keiser JA, Haleen SJ, Walker DM, Olszewski B, Schroeder RL, et al. Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist. J Pharmacol Exp Ther 1995; 273:1410-1417.
26. Benetos A, Albaladejo P, Levy BI, Safar ME. Acute and long-term effects of angiotensin converting enzyme inhibition on larger arteries and cardiac hypertrophy: mechanical and structural parameters. J Hypertens Suppl 1994; 12:S21-S29.
27. Duguay D, deBlois D. Differential regulation of Akt, caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine. Br J Pharmacol 2007; 151:1315-1323.
28. De Blois D, Tea BS, Beaudry D, Hamet P. Regulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage. Can J Physiol Pharmacol 2005; 83:29-41.
29. Woolard J, Hale TM, Bushfield TL, Adams MA. Persistent lowering of arterial pressure after continuous and intermittent therapy. J Hypertens 2003; 21:813-820.
30. Sudano I, Hermann M, Ruschitzka FT. Endothelin-receptor antagonists in arterial hypertension: further indications? Curr Hypertens Rep 2007; 9:59-65.
31. Kusaka Y, Kelly RA, Williams GH, Kifor I. Coronary microvascular endothelial cells cosecrete angiotensin II and endothelin-1 via a regulated pathway. Am J Physiol Heart Circ Physiol 2000; 279:H1087-H1096.
32. Barton M, Shaw S, Uscio LV, Moreau P, Luscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238:861-865.
33. Moreau P, D'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997; 96:1593-1597.
34. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, et al. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991; 18:165-170.
35. D'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Luscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997; 29 (1 Pt 2):435-441.
36. Baba T, Kanda T, Kobayashi I. Reduction of cardiac endothelin-1 by angiotensin II type 1 receptor antagonist in viral myocarditis of mice. Life Sci 2000; 67:587-597.
37. Lariviere R, Lebel M, Kingma I, Grose JH, Boucher D. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am J Hypertens 1998; 11 (8 Pt 1):989-997.
38. Tanabe A, Naruse M, Seki T, Adachi C, Yoshimoto T, Imaki T, et al. Gene expression of endothelin-1 and endothelial-type nitric oxide synthase in cardiovascular tissues of stroke-prone spontaneously hypertensive rats/ Izm: effects of the angiotensin-converting enzyme inhibitor aracepril. J Cardiovasc Pharmacol 1998; 31 (Suppl 1):S395-S398.
39. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685-1697.
40. Kostis JB, Espeland MA, Appel L, Johnson KC, Pierce J, Wofford JL. Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? Trial of Nonpharmacologic Interventions in the Elderly (TONE) Cooperative Research Group. Am J Cardiol 1998; 82:1501-1508.
41. Sieg-Dobrescu D, Burnier M, Hayoz D, Brunner HR, Waeber B. The return of increased blood pressure after discontinuation of antihypertensive treatment is associated with an impaired postischemic skin blood flow response. J Hypertens 2001; 19:1387-1392.
42. Aylett M, Creighton P, Jachuck S, Newrick D, Evans A. Stopping drug treatment of hypertension: experience in 18 British general practices. Br J Gen Pract 1999; 49:977-980.
43. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761-2788.
44. McInnes GT. How important is optimal blood pressure control? Clin Ther 2004; 26 (Suppl A):A3-11.
45. Rosendorff C, Black HR. Evidence for a lower target blood pressure for people with heart disease. Curr Opin Cardiol 2009; 24:318-324.
46. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009; 54:32-39.
47. Sevilla MA, Voces F, Carron R, Guerrero EI, Ardanaz N, San Roman L, et al. Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. Life Sci 2004; 75:881-891.
48. Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007; 9:760-769.